Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MINDSET 2: KarXT + KarX-EC in Alzheimer's Disease
NCT06976203Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2025
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 17
01
Overview
A Phase 3 trial of xanomeline, KarX-EC in Alzheimer's disease (AD), sponsored by Bristol Myers Squibb. Started Jul 2025; status: recruiting.
02
Drugs
xanomelineKarX-EC
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06976203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06976203.